FilingReader Intelligence
Zhejiang Wolwo begins dermatitis diagnostic patch trial
August 11, 2025 at 08:11 AM UTC•By FilingReader AI
Zhejiang Wolwo Bio-Pharmaceutical announced first subject enrollment for its dermatitis diagnostic patch in Phase I clinical trials at Jining First People's Hospital.
The patch is classified as a Class 1 therapeutic biological product for diagnosing allergic contact dermatitis related to sensitization to Balsam of Peru, p-phenylenediamine, and formaldehyde.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300357•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Wolwo Bio-Pharmaceutical publishes news
Free account required • Unsubscribe anytime